硼替佐米联合沙利度胺地塞米松治疗对多发性骨髓瘤患者炎症指标免疫功能的影响  

Efficacy of bortezomib,thalidomide and dexamethasone on patients with multiple myeloma

作　　者：朱锐锋 周水阳 包维莺[1] 王恒石 范璐 王利萍 王小艳 Zhu Ruifeng;Zhou Shuiyang;Bao Weiying;Wang Hengshi;Fan Lu;Wang Liping;Wang Xiaoyan(Department ofHematology,Songjiang Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 201699,China)

机构地区：[1]上海交通大学医学院附属松江医院血液科,201699

出　　处：《山西医药杂志》2025年第2期99-102,共4页Shanxi Medical Journal

摘　　要：目的探讨硼替佐米和沙利度胺、地塞米松联合治疗对多发性骨髓瘤患者的影响。方法选取2020年8月至2023年8月上海市松江区中心医院收治的100例多发性骨髓瘤患者为研究对象,按照随机数字表法分为2组,每组各50例。对照组予以沙利度胺、地塞米松治疗,观察组于对照组基础上加用硼替佐米。对比2组临床疗效、炎症指标、免疫功能、骨代谢指标、不良反应。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05);观察组治疗后的血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)、C反应蛋白(CRP)、白细胞介素-17(IL-17)、T细胞亚群CD8+、Ⅰ型胶原C端肽(CTX-Ⅰ)均低于对照组,CD4+、CD3+、CD4+/CD8+、骨钙素(BGP)、碱性磷酸酶(ALP)均高于对照组,差异有统计学意义(P<0.05);2组不良反应差异无统计学意义(P>0.05)。结论在多发性骨髓瘤患者中应用硼替佐米联合沙利度胺、地塞米松治疗效果显著,可促进患者免疫功能改善,减轻炎症反应,增强骨代谢能力,且安全性高。Objective The efficacy of bortezomib,thalidomide,and dexamethasone in treating patients with multiple myeloma was investigated.Methods A total of 100 multiple myeloma patients admitted to Songjiang District Central Hospital in Shanghai between August 2020 and August 2023 were enrolled as subjects for this study.These patients were randomly assigned into two groups(50 each)by a random number table.The control group received thalidomide and dexamethasone,whereas the observation group was administered bortezomib in addition to the control group's regimen.The clinical efficacy,inflammation markers,immune function,bone metabolism indicators,and adverse reactions between the two groups were compared.Results The observation group demonstrated a higher overall clinical effective rate compared to the control group,with a statistically significant difference(P<0.05).Post-treatment levels of vascular endothelial growth factor(VEGF),interleukin-6(IL-6),C-reactive protein(CRP),interleukin-17(IL-17),T lymphocyte subset CD8+,and type I collagen C-terminal peptide(CTX-I)were lower in the observation group than those in the control group.Conversely,CD4+,CD3+,CD4+/CD8+ratios,osteocalcin(BGP),and alkaline phosphatase(ALP)levels were higher,with all differences being statistically significant(P<0.05).Adverse reactions between the two groups were comparable,with no statistically significant difference(P>0.05).Conclusion The combined use of bortezomib with thalidomide and dexamethasone in the treatment of multiple myeloma patients yields significant therapeutic benefits,enhances immune function,reduces inflammatory responses,improves bone metabolism,and exhibits a high level of safety.

关 键 词：多发性骨髓瘤 地塞米松 硼替佐米 沙利度胺 炎症指标 免疫功能 

分 类 号：R733.3[医药卫生—肿瘤]